---
title: "Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/601607.SH.md"
symbol: "601607.SH"
name: "Shanghai Pharmaceuticals Holding Co.,Ltd."
industry: "Health Care Distributors"
datetime: "2026-05-21T11:48:06.610Z"
locales:
  - [en](https://longbridge.com/en/quote/601607.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/601607.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/601607.SH.md)
---

# Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH)

## Company Overview

Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as invests in equity.

| Item | Detail |
|------|--------|
| Industry | Health Care Distributors |
| Exchange | CN Market |
| Website | [www.sphchina.com](https://www.sphchina.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.43)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 4 / 23 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.43% |  |
| Net Profit YoY | 33.75% |  |
| P/B Ratio | 0.80 |  |
| Dividend Ratio | 2.47% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 61514490060.93 |  |
| Revenue | 287525014518.18 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.73% | B |
| Profit Margin | 2.02% | C |
| Gross Margin | 10.75% | E |
| Revenue YoY | 4.43% | C |
| Net Profit YoY | 33.75% | B |
| Total Assets YoY | 4.20% | C |
| Net Assets YoY | 7.23% | B |
| Cash Flow Margin | 126.50% | B |
| OCF YoY | 4.43% | C |
| Turnover | 1.25 | A |
| Gearing Ratio | 61.14% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Pharmaceuticals Holding Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.43%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "33.75%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.80",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.47%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "61514490060.93",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "287525014518.18",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.73%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "2.02%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "10.75%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "4.43%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "33.75%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.20%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.23%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "126.50%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "4.43%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "1.25",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "61.14%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 10.61 | 4/23 | 15.42 | 11.48 | 11.09 |
| PB | 0.80 | 3/23 | 0.92 | 0.88 | 0.84 |
| PS (TTM) | 0.21 | 8/23 | 0.25 | 0.24 | 0.23 |
| Dividend Yield | 2.47% | 10/23 | 2.46% | 2.35% | 1.62% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | HUADONG MEDICINE (000963.SZ) | B | C | A | B | C | B |
| 02 | SINOPHARM(CNCM LTD) (600511.SH) | C | C | A | C | C | B |
| 03 | TIBET PHARMA (600211.SH) | A | C | C | B | C | B |
| 04 | Shanghai Pharma (601607.SH) | C | C | A | D | C | C |
| 05 | GYBYS (600332.SH) | C | C | A | C | C | C |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-30T16:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 50% |
| Overweight | 2 | 20% |
| Hold | 2 | 20% |
| Underweight | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.50 |
| Highest Target | 25.88 |
| Lowest Target | 12.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/601607.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/601607.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/601607.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/601607.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**